Hernexeos — daridorexant class
Named-patient access overview. Hernexeos is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Hernexeos
Hernexeos (daridorexant class) is manufactured by Idorsia (verify) and indicated for Insomnia — OUT OF SCOPE (daridorexant class = DEA Schedule IV dual orexin receptor antagonist; PlatformCo does not handle controlled substances. Fatima's DEA-registered entity may pursue separately. Note: drug-name mapping 'Hernexeos' is uncertain — verify FDA label before any future action.). It is a HER2 TKI approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Hernexeos
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Hernexeos for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Hernexeos is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Hernexeos in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Start a request for Hernexeos
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.